SSR 103800

Drug Profile

SSR 103800

Alternative Names: SSR 103800A; SSR103800

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antipsychotics
  • Mechanism of Action Glycine reuptake inhibitors; Glycine transporter 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia in France (PO)
  • 03 Sep 2008 Pharmacodynamics data from preclinical trials in Schizophrenia presented at the 21st Annual Congress of the European College of Neuropsychopharmacology (ECNP-2008)
  • 17 Oct 2007 Pharmacodynamics data from a preclinical trial in an animal model of Schizophrenia presented at the 20th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top